Tocilizumab before or during CAR-T therapy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests whether giving tocilizumab (a drug that calms inflammation) before CAR-T cell therapy helps prevent side effects. It compares using it ahead of time versus only when needed. You may be eligible if you are scheduled for CAR-T therapy for lymphoma, leukemia, or myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to receive CAR-T cell therapy for lymphoma, leukemia, or myeloma.
- You are at least 18 years old.
- You have not received tocilizumab in the last 3 months.
- You have not taken any other experimental drug in the last 8 weeks.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study period (unless you use highly effective birth control).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a spinal injection of three common chemotherapy drugs can reduce or prevent serious brain and nerve side effects in people receiving CAR-T cell therapy for cancer.
This study tests an experimental drug, CTO1681, that may help prevent or treat cytokine release syndrome (CRS) — a common side effect of CAR T-cell therapy. It could make the recovery period safer and more comfortable.
This trial adds a low dose of radiation to the entire body before CAR T cell therapy for patients with acute lymphoblastic leukemia. The goal is to see if this extra step helps the CAR T cells work better, without adding much extra discomfort.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
Hear when a new Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.